<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">Other experimental vaccines in advanced development for potential administration during pregnancy include an aluminum hydroxide adjuvanted RSV stabilized pre-fusion F subunit vaccine, which began enrollment in a phase IIB placebo controlled randomized clinical trial in pregnant women in the US in August 2019 (Pfizer. 
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04032093" id="ir0050" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04032093</ext-link> â€“ 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04032093" id="ir0055" xmlns:xlink="http://www.w3.org/1999/xlink">
  <underline>https://clinicaltrials.gov/ct2/show/NCT04032093</underline>
 </ext-link>), and an unadjuvanted pre-F subunit vaccine that will begin phase II evaluation in pregnant women in 2020 after having completed dose ranging immunogenicity and safety evaluation in non-pregnant healthy women (GSK Biologicals, GSK3888550A, 
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03674177" id="ir0060" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03674177</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03674177" id="ir0065" xmlns:xlink="http://www.w3.org/1999/xlink">
  <underline>https://clinicaltrials.gov/ct2/show/NCT03674177</underline>
 </ext-link>) (
 <xref rid="t0015" ref-type="table">Table 2</xref>).
</p>
